AbolerIS Pharma Presents New Data Supporting CD45RC as a Novel Therapeutic Target and Potential Biomarker in Sjögren's Disease at EULAR 2026

- Findings demonstrate strong correlation between CD45RC expression and lymphocytic infiltration in salivary glands, supporting its potential as both an early biomarker and therapeutic target in Sjögren disease GOSSELIES, Belgium and NANTES, France, June 4, 2026 /PRNewswire/ -- AbolerIS...